Multi-Omics reveals SPP1+ malignant and CXCR4+ TAM crosstalk predicts immunotherapy response in lung adenocarcinoma
A tumor microenvironment signature might predict which lung cancer patients will respond to immunotherapy, enabling smarter treatment selection.
Single-cell and spatial transcriptomics analysis of LUAD identified a tumor microenvironment crosstalk mechanism (SPP1+ malignant cells × CXCR4+ tumor-associated macrophages) that drives T cell exhaustion and immunotherapy resistance. The SPP1+/CXCR4+ infiltration signature may serve as a predictive biomarker for patient selection for immune checkpoint inhibitor therapy.
What the study was
- Study design
- Multi-omics analysis (scRNA-seq + spatial transcriptomics + in vitro validation)
- Population
- LUAD tumor samples; no clinical cohort specified
- Category
- Treatment Innovation
- Maturity
- Exploratory
- Journal
- Discover Oncology
Why it surfaced
Multi-omics discovery study identifying novel TME-based immunotherapy resistance mechanism in LUAD; spatially validated; patient-selection biomarker potential.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.